Literature DB >> 19655119

Future treatment strategies for neuropathic pain.

Fabien Marchand1, Nicholas G Jones, Stephen B McMahon.   

Abstract

The prevalence of people suffering from chronic pain is extremely high and pain affects millions of people worldwide. As such, persistent pain represents a major health problem and an unmet clinical need. The reason for the high incidence of chronic pain patients is in a large part due to a paucity of effective pain control. An important reason for poor pain control is undoubtedly a deficit in our understanding of the underlying causes of chronic pain and as a consequence our arsenal of analgesic therapies is limited. However, there is considerable hope for the development of new classes of analgesic drugs by targeting novel processes contributing to clinically relevant pain. In this chapter we highlight a number of molecular species which are potential therapeutic targets for future neuropathic pain treatments. In particular, the roles of voltage-gated ion channels, neuroinflammation, protein kinases and neurotrophins are discussed in relation to the generation of neuropathic pain and how by targeting these molecules it may be possible to provide better pain control than is currently available.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19655119     DOI: 10.1007/978-3-540-79090-7_17

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  6 in total

1.  Overcoming obstacles to developing new analgesics.

Authors:  Clifford J Woolf
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

Review 2.  Foamy virus: an available vector for gene transfer in neural cells and other nondividing cells.

Authors:  Yingying Zhang; Yongjuan Liu; Guoguo Zhu; Yanyan Qiu; Biwen Peng; Jun Yin; Wanhong Liu; Xiaohua He
Journal:  J Neurovirol       Date:  2010-10-25       Impact factor: 2.643

Review 3.  Pharmacogenetics of new analgesics.

Authors:  Jörn Lötsch; Gerd Geisslinger
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

4.  Downregulation of microRNA‑29c reduces pain after child delivery by activating the oxytocin‑GABA pathway.

Authors:  Caijuan Li; Xian Wang; Guangfen Zhang; Yao Zhang; Fan Xia; Shiqin Xu; Xiaofeng Shen
Journal:  Mol Med Rep       Date:  2020-06-26       Impact factor: 2.952

5.  Criticality and degeneracy in injury-induced changes in primary afferent excitability and the implications for neuropathic pain.

Authors:  Stéphanie Ratté; Yi Zhu; Kwan Yeop Lee; Steven A Prescott
Journal:  Elife       Date:  2014-04-01       Impact factor: 8.140

Review 6.  Therapeutic Strategies for Neuropathic Pain: Potential Application of Pharmacosynthetics and Optogenetics.

Authors:  Gum Hwa Lee; Sang Seong Kim
Journal:  Mediators Inflamm       Date:  2016-01-13       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.